Informe del mercado biofarmacéutico por indicación (enfermedades autoinmunes, oncología, trastornos metabólicos y otros), clase (proteínas recombinantes, anticuerpos monoclonales, proteínas purificadas) y región 2024-2032

Informe del mercado biofarmacéutico por indicación (enfermedades autoinmunes, oncología, trastornos metabólicos y otros), clase (proteínas recombinantes, anticuerpos monoclonales, proteínas purificadas) y región 2024-2032

Report Format: PDF+Excel | Report ID: SR112025A14328

Language of the Report – English

Sin embargo, el informe puede estar disponible en español por un costo adicional.

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction
5   Global Biopharmaceutical Market

    5.1    Market Performance and Forecast
        5.1.1 Current Performance (2018-2023)
        5.1.2 Market Forecast (2024-2032)
    5.2    Impact of COVID-19
    5.3    Market by Region
        5.3.1 Current Performance (2018-2023)
        5.3.2 Market Forecast (2024-2032)
    5.4    Market by Indication
        5.4.1 Autoimmune Diseases
        5.4.2 Oncology
        5.4.3 Metabolic Disorders
        5.4.4 Others
    5.5    Market by Class
        5.5.1 Recombinant Proteins
            5.5.1.1 Current Performance (2018-2023)
            5.5.1.2 Market Forecast (2024-2032)
        5.5.2 Monoclonal Antibodies
            5.5.2.1 Current Performance (2018-2023)
            5.5.2.2 Market Forecast (2024-2032)
        5.5.3 Purified Proteins
            5.5.3.1 Current Performance (2018-2023)
            5.5.3.2 Market Forecast (2024-2032)
    5.6    Competitive Landscape
        5.6.1 Top Biopharmaceutical Players
        5.6.2 Top Biopharmaceutical Drugs       
    5.7    Value Chain Analysis
    5.8    Porter’s Five Forces Analysis
        5.8.1 Overview
        5.8.2 Bargaining Power of Buyers
        5.8.3 Bargaining Power of Suppliers
        5.8.4 Degree of Rivalry
        5.8.5 Threat of New Entrants
        5.8.6 Threat of Substitutes
6   North America
    6.1    United States
        6.1.1 Market Performance (2018-2023)
        6.1.2 Market by Class
            6.1.2.1 Recombinant Proteins
            6.1.2.2 Monoclonal Antibodies
            6.1.2.3 Purified Proteins
        6.1.3 Top Players
        6.1.4 Market Forecast (2024-2032)
    6.2    Canada
        6.2.1 Market Performance (2018-2023)
        6.2.2 Market by Class
            6.2.2.1 Recombinant Proteins
            6.2.2.2 Monoclonal Antibodies
            6.2.2.3 Purified Proteins
        6.2.3 Top Players
        6.2.4 Market Forecast (2024-2032)
7   Latin America
    7.1    Mexico
        7.1.1 Market Performance (2018-2023)
        7.1.2 Market by Class
            7.1.2.1 Recombinant Proteins
            7.1.2.2 Monoclonal Antibodies
            7.1.2.3 Purified Proteins
        7.1.3 Top Players
        7.1.4 Market Forecast (2024-2032)
    7.2    Brazil
        7.2.1 Market Performance (2018-2023)
        7.2.2 Market by Class
            7.2.2.1 Recombinant Proteins
            7.2.2.2 Monoclonal Antibodies
            7.2.2.3 Purified Proteins
        7.2.3 Top Players
        7.2.4 Market Forecast (2024-2032)
    7.3    Argentina
        7.3.1 Market Performance (2018-2023)
        7.3.2 Market by Class
            7.3.2.1 Recombinant Proteins
            7.3.2.2 Monoclonal Antibodies
            7.3.2.3 Purified Proteins
        7.3.3 Top Players
        7.3.4 Market Forecast (2024-2032)
8   Europe
    8.1    Germany
        8.1.1 Market Performance (2018-2023)
        8.1.2 Market by Class
            8.1.2.1 Recombinant Proteins
            8.1.2.2 Monoclonal Antibodies
            8.1.2.3 Purified Proteins
        8.1.3 Top Players
        8.1.4 Market Forecast (2024-2032)
    8.2    France
        8.2.1 Market Performance (2018-2023)
        8.2.2 Market by Class
            8.2.2.1 Recombinant Proteins
            8.2.2.2 Monoclonal Antibodies
            8.2.2.3 Purified Proteins
        8.2.3 Top Players
        8.2.4 Market Forecast (2024-2032)
    8.3    Italy
        8.3.1 Market Performance (2018-2023)
        8.3.2 Market by Class
            8.3.2.1 Recombinant Proteins
            8.3.2.2 Monoclonal Antibodies
            8.3.2.3 Purified Proteins
        8.3.3 Top Players
        8.3.4 Market Forecast (2024-2032)
    8.4    Spain
        8.4.1 Market Performance (2018-2023)
        8.4.2 Market by Class
            8.4.2.1 Recombinant Proteins
            8.4.2.2 Monoclonal Antibodies
            8.4.2.3 Purified Proteins
        8.4.3 Top Players
        8.4.4 Market Forecast (2024-2032)
    8.5    United Kingdom
        8.5.1 Market Performance (2018-2023)
        8.5.2 Market by Class
            8.5.2.1 Recombinant Proteins
            8.5.2.2 Monoclonal Antibodies
            8.5.2.3 Purified Proteins
        8.5.3 Top Players
        8.5.4 Market Forecast (2024-2032)
    8.6    Russia
        8.6.1 Market Performance (2018-2023)
        8.6.2 Market by Class
            8.6.2.1 Recombinant Proteins
            8.6.2.2 Monoclonal Antibodies
            8.6.2.3 Purified Proteins
        8.6.3 Top Players
        8.6.4 Market Forecast (2024-2032)
    8.7    Turkey
        8.7.1 Market Performance (2018-2023)
        8.7.2 Market by Class
            8.7.2.1 Recombinant Proteins
            8.7.2.2 Monoclonal Antibodies
            8.7.2.3 Purified Proteins
        8.7.3 Top Players
        8.7.4 Market Forecast (2024-2032)
9   Asia Pacific
    9.1    Japan
        9.1.1 Market Performance (2018-2023)
        9.1.2 Market by Class
            9.1.2.1 Recombinant Proteins
            9.1.2.2 Monoclonal Antibodies
            9.1.2.3 Purified Proteins
        9.1.3 Top Players
        9.1.4 Market Forecast (2024-2032)
    9.2    China
        9.2.1 Market Performance (2018-2023)
        9.2.2 Market by Class
            9.2.2.1 Recombinant Proteins
            9.2.2.2 Monoclonal Antibodies
            9.2.2.3 Purified Proteins
        9.2.3 Top Players
        9.2.4 Market Forecast (2024-2032)
    9.3    Australia
        9.3.1 Market Performance (2018-2023)
        9.3.2 Market by Class
            9.3.2.1 Recombinant Proteins
            9.3.2.2 Monoclonal Antibodies
            9.3.2.3 Purified Proteins
        9.3.3 Top Players
        9.3.4 Market Forecast (2024-2032)
    9.4    South Korea
        9.4.1 Market Performance (2018-2023)
            9.4.1.1 Recombinant Proteins
            9.4.1.2 Monoclonal Antibodies
            9.4.1.3 Purified Proteins
        9.4.2 Top Players
        9.4.3 Market Forecast (2024-2032)
    9.5    India
        9.5.1 Market Performance (2018-2023)
        9.5.2 Market by Class
            9.5.2.1 Recombinant Proteins
            9.5.2.2 Monoclonal Antibodies
            9.5.2.3 Purified Proteins
        9.5.3 Top Players
        9.5.4 Market Forecast (2024-2032)
    9.6    Indonesia
        9.6.1 Market Performance (2018-2023)
        9.6.2 Market by Class
            9.6.2.1 Recombinant Proteins
            9.6.2.2 Monoclonal Antibodies
            9.6.2.3 Purified Proteins
        9.6.3 Top Players
        9.6.4 Market Forecast (2024-2032)
10  SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11  Competitive Landscape
    11.1    Market Structure
    11.2    Key Players
    11.3    Profiles of Key Players
       11.3.1    AbbVie Inc.
       11.3.2    Amgen Inc
       11.3.3    Biogen Inc.
       11.3.4    Eli Lilly and Company
       11.3.5    F. Hoffmann-La Roche AG
       11.3.6    Johnson & Johnson
       11.3.7    Merck & Co. Inc.
       11.3.8    Novo Nordisk A/S
       11.3.9    Pfizer Inc.
       11.3.10    Sanofi S.A

Informe del mercado biofarmacéutico por indicación (enfermedades autoinmunes, oncología, trastornos metabólicos y otros), clase (proteínas recombinantes, anticuerpos monoclonales, proteínas purificadas) y región 2024-2032
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials